Clinical trial · Interventional
Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients
NCT06725043CI-TRIAL-00083561completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study was conducted to examine the effect of ultrasound acupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Patients and Their Partners | — | UNRESOLVED | — |
| Oxaliplatin-induced Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo therapeutic ultrasound | Device | — | UNRESOLVED |
| Therapeutic ultrasound | Device | — | UNRESOLVED |
| Traditional physical therapy program | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Active
- description
- Therapeutic ultrasound (1 MHz) Pulsed mode at bilateral acupuncture points of PC6, PC7, BL60 andKI1
- interventionNames
- Device: Therapeutic ultrasound
- Other: Traditional physical therapy program
- type
- PLACEBO_COMPARATOR
- label
- Experime
- description
- Placebo Therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI1
- interventionNames
- Device: Placebo therapeutic ultrasound
- Other: Traditional physical therapy program
Primary outcomes (2)
- measure
- Pain level assessment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: \- The subject selection was according to the following criteria: * Adults their ages ranged from 20 to 70 years old. * Receiving or have received chemotherapy treatment for colon or rectal cancer. * Chemotherapy regimen included the agent oxaliplatin. * Patients diagnosed with neuropathy by the oncologist. * Both sexes. * No neuropathy prior to oxaliplatin treatment. * No documented or observable psychiatric or neurological disorders that would interfere with study participation (eg, dementia or psychosis) * Stage II, III and IV colon or rectal cancer. * Hands and Feets were the most affected by CIPN. * The first dose of oxaliplatin was from 4 months or more. Exclusion Criteria: * The potential participants were excluded in the following conditions: * Another malignancy * Patients with severe or unstable cardiorespiratory or musculoskeletal diseases that may influence the accuracy of quantitative sensory testing results. * Participants who cannot remain on the same medications throughout the study period with minor dose adjustments allowed. * Contraindications to therapeutic ultrasound including active cancer in region of hands or feet, presence of deep vein thrombosis, complete numbness in hands or feet (representing severe CIPN), metal or plastic implantation * Peripheral vascular disease in hands or feet.
References
Publications (0)
Data not yet available
No reference posted for this study.